Low expression of the apolipoprotein B mRNA-editing transgene in mice reduces LDL levels but does not cause liver dysplasia or tumors

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 6, 1998, Pages 1013-1020

  Qian, Xiaobing ^a,d   Balestra, Maureen E ^a   Yamanaka, Shinya ^c   Borén, Jan ^a   Lee, Isabelle ^a   Innerarity, Thomas L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

Author keywords

APOBEC 1; Cholesterol; NAT1; RNA editing; Tumorigenesis

Indexed keywords

APOLIPOPROTEIN B;

ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CARCINOGENESIS; GENE THERAPY; LIPID METABOLISM; LIVER FUNCTION; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA EDITING; TRANSGENIC MOUSE;

EID: 0031776085     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.6.1013     Document Type: Article

References (19)

1. Chan L. Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J Biol Chem. 1992;267: 25621-25624.
2. Innerarity TL. Plasma lipoproteins. In: Dulbecco R, eds. Encyclopedia of Human Biology. Vol 6. San Diego, Calif: Academic Press; 1991:23-35.
3. Innerarity TL, Borén J, Yamanaka S, Olofsson S-O. Biosynthesis of apolipoprotein B48-containing lipoproteins: regulation by novel post-transcriptional mechanisms. J Biol Chem. 1996;271:2353-2356.
4. Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell. 1987;50:831-840.
5. Johnson DF, Poksay KS, Innerarity TL. The mechanism for apo-B mRNA editing is deamination. Biochem Biophys Res Commun. 1993;195: 1204-1210.
6. Mahley RW, Rail SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York, NY: McGraw-Hill; 1995:1953-1980.
7. Pitas RE, Innerarity TL, Mahley RW. Cell surface receptor binding of phospholipid · protein complexes containing different ratios of receptor-active and inactive E apoprotein. J Biol Chem. 1980;255:5454-5460.
8. Innerarity TL, Mahley RW. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry. 1978;17:1440-1447.
9. Elovson J, Huang YO, Baker N, Kannan R. Apolipoprotein B is structurally and metabolically heterogeneous in the rat. Proc Natl Acad Sci U S A. 1981;78:157-161.
10. Greeve J, Altkemper I, Dieterich J-H, Greten H, Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res. 1993;34:1367-1383.
11. Teng B, Burant CF, Davidson NO. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science. 1993;260: 1816-1819.
12. Young SG. Recent progress in understanding apolipoprotein B. Circulation. 1990;82:1574-1594.
13. Teng B, Blumenthal S, Forte T, Navaratnam N, Scott J, Gotto AM Jr, Chan L. Adenovirus-mediated gene transfer of rat apolipoprotein B mRNA-editing protein in mice virtually eliminates apolipoprotein B-100 and normal low density lipoprotein production. J Biol Chem. 1994;269: 29395-29404.
14. Kozarsky KF, Bonen DK, Giannoni F, Funahashi T, Wilson JM, Davidson NO. Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec- 1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits. Hum Gene Ther. 1996;7: 943-957.
15. Hughes SD, Rouy D, Navaratnam N, Scott J, Rubin EM. Gene transfer of cytidine deaminase apoBEC-1 lowers lipoprotein(a) in transgenic mice and induces apolipoprotein B editing in rabbits. Hum Gene Ther. 1996; 7:39-49.
16. Teng B, Ishida B, Forte TM, Blumenthal S, Song L-Z, Gotto AM Jr, Chan L. Effective lowering of plasma, LDL, and esterified cholesterol in LDL receptor-knockout mice by adenovirus-mediated gene delivery of apoB mRNA editing enzyme (Apobec 1). Arterioscler Thromb Vasc Biol. 1997; 17:889-897.
17. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, Taylor JM, Innerarity TL. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci U S A. 1995;92:8483-8487.
18. Yamanaka S, Poksay KS, Driscoll DM, Innerarity TL. Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif. J Biol Chem. 1996;271:11506-11510.
19. Yamanaka S, Poksay KS, Arnold KS, Innerarity TL. A novel translational represser mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme. Gene Dev. 1997;11:321-333.